Heinemann, V., Niedzwiecki, D., Pearline, R. V., Grothey, A., Hochster, H. S., Goldberg, R. M., … O’Neil, B. H. (2015). Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405. In Journal of Clinical Oncology (Vol. 33, pp. 3585–3585). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2015.33.15_suppl.3585

Heinemann, Volker, Donna Niedzwiecki, Rachel V. Pearline, Axel Grothey, Howard S. Hochster, Richard M. Goldberg, Federico Innocenti, et al. “Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405.” In Journal of Clinical Oncology, 33:3585–3585. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.3585.

Heinemann V, Niedzwiecki D, Pearline RV, Grothey A, Hochster HS, Goldberg RM, et al. Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015. p. 3585–3585.

Heinemann, Volker, et al. “Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405.” Journal of Clinical Oncology, vol. 33, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2015, pp. 3585–3585. Crossref, doi:10.1200/jco.2015.33.15_suppl.3585.

Heinemann V, Niedzwiecki D, Pearline RV, Grothey A, Hochster HS, Goldberg RM, Innocenti F, Mayer RJ, Schilsky RL, Blanke CD, Bertagnolli MM, Venook AP, Stinzing S, O’Neil BH. Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015. p. 3585–3585.